Aurobindo's strong European, US prospects keeping analysts bullish

As the pricing pressure in US generics market recedes, the company is also expected to fair well, say analysts, who see growth impetus coming from its recent acquisitions in the US and Europe

The Aurobindo stock is an outlier in the pharma sector, in which many companies have been faced with regulatory, growth, and other issues. 

On Tuesday, it hit a 52-week high, taking the gains to 15 per cent from its February lows. Performance in the US and Europe is a key factor behind the firm figuring in the top pharma picks of analysts. 

The firms has continued to grow well, driven by its large number of filings and niche range of products such as injectables. Thanks to a diversified product basket and limited dependence on any single product, the impact of pricing pressure